ALENTIS’ UNIQUE CLDN1 MONOCLONAL ANTIBODIES
CAN REVERT THE EXTRACELLULAR MATRIX TO ITS
HEALTHY STATE IN CANCERS AND ORGAN TISSUES
We develop a portfolio of first-in-class antibodies that specifically bind exposed CLDN1 outside of tight junctions to treat cancer and reverse fibrosis.
ALE.C04 is a first-in-class monoclonal antibody that specifically targets exposed CLDN1 on cancer cells. It is designed to treat cancer in two ways: remodeling of the extracellular matrix, leading to improved immune cell trafficking and direct tumor cell killing through the effector function.
ALE.C04 received Fast Track designation from the Food and Drug Administration for the treatment of CLDN1+ HNSCC.
A Phase 1/2 first-in-human clinical trial is ongoing in head and neck squamous cell carcinoma (HNSCC). More information about the study can be found on clinicaltrials.gov.
Lixudebart is a first-in-class monoclonal antibody that specifically targets a unique CLDN1 epitope exposed in fibrotic tissue to stop the progression of and even reverse organ fibrosis.
In a Phase 1 study in healthy volunteers, lixudebart was well tolerated and without any serious safety concerns. A Phase 1b clinical trial is ongoing for liver fibrosis and a Phase 2 clinical trial is ongoing for kidney fibrosis. More information on the studies can be found on clinicaltrials.gov.
Next Generation anti-CLDN1 assets
At Alentis we develop the next generation of anti-CLDN1 antibodies to potentiate the efficacy of cancer treatments. Among others, we explore antibody-drug conjugates (ADCs) and potential other payloads and approaches.